Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • Based on current prices, the company has particularly high valuation levels.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • Below the resistance at 118.73 USD, the stock shows a negative configuration when looking looking at the weekly chart.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
CELGENE CORPORATION-8.35%85 030
JOHNSON & JOHNSON21.53%379 175
NOVARTIS12.15%218 773
PFIZER9.30%215 837
ROCHE HOLDING LTD.3.40%209 423
MERCK AND COMPANY-6.96%153 659
AMGEN18.98%128 363
SANOFI-4.84%109 438
BRISTOL-MYERS SQUIBB COMPAN..5.82%103 145
NOVO NORDISK A/S29.17%102 404
BAYER5.62%102 387
ABBOTT LABORATORIES42.38%95 629
ELI LILLY AND COMPANY16.75%95 432
GLAXOSMITHKLINE-17.57%85 531
ASTRAZENECA7.81%82 666
ALLERGAN PLC-21.49%57 457
More Results
Financials ($)
Sales 2017 12 967 M
EBIT 2017 7 286 M
Net income 2017 4 215 M
Debt 2017 4 463 M
Yield 2017 -
P/E ratio 2017 21,34
P/E ratio 2018 15,71
EV / Sales 2017 6,96x
EV / Sales 2018 5,75x
Capitalization 85 849 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart CELGENE CORPORATION
Duration : Period : Day
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Duration : Period : Week
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders